A PHASE 1B, OPEN-LABEL, DOSE ESCALATION WITH AN EXPANSION TRIAL OF A IN COMBINATION WITH B OR A PLUS STANDARD OF CARE IN PATIENTS WITH XXX CANCER ELIGIBLE FOR SECOND LINE TREATMENT

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521582-27-00

Acronym

LCB-2301-002

Enrollment

60

Registered

2025-06-30

Start date

2025-07-03

Completion date

Unknown

Last updated

2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

XXX CANCER ELIGIBLE FOR SECOND LINE TREATMENT

Interventions

None listed

Sponsors

NovImmune S.A.

Lead SponsorINDUSTRY

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026